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A dissolution test for tablets containing 100 mg of lamotrigine was developed and validated. The 
dissolution test was applied to compare the dissolution profile of Neural® with the reference product 
Lamictal®. The analysis procedure was carried out using a simple ultraviolet method at 267 nm. After 
the determination of solubility and sink conditions, the parameters selected were paddles at 50 rpm, 
900 mL of 0.01 M hydrochloric acid, and 30 minutes duration (single point). This method was validated 
for specificity, linearity, accuracy, precision and robustness. Lamotrigine stability was also evaluated 
in dissolution medium.
Uniterms: Lamotrigine. Dissolution test/validation. Medicines/quality control.
A finalidade deste estudo foi desenvolver e validar um método de dissolução para o fármaco lamotrigina na 
forma farmacêutica comprimido. Este método também foi utilizado para comparar o perfil de dissolução 
entre o Neural® e o produto de referência Lamictal®. O procedimento analítico foi realizado utilizando-se 
espectrofotometria de absorção no ultravioleta (267 nm) como forma de quantificação do fármaco. Após 
a determinação da solubilidade e das condições sink, os parâmetros selecionados foram: pás (50 rpm), 
900 mL de ácido clorídrico 0.01 M e o tempo de 30 minutos (único ponto). Este método foi validado 
através da especificidade, linearidade, exatidão, precisão e robustez. A estabilidade da lamotrigina também 
foi avaliada no meio de dissolução. 
Unitermos: Lamotrigina. Teste de dissolução/validação. Medicamentos/controle de qualidade. 
INTRODUCTION
Drug absorption after oral administration depends 
on the release of the drug’s active substance from the drug 
formulation, whereas clinical effect depends on the amount 
of the drug that reaches the site of action (Ansel, 2000; 
Shargel et al., 2005). Dissolution tests are an important 
tool in various steps of drug production and quality con-
trol. The dissolution tests for immediate release, solid, oral 
dosage forms such as tablets, are used to assess lot-to-lot 
quality of a drug product; to guide development of new 
drug formulations and ensure consistent product quality 
and performance after certain changes such as alterations 
in formulation and the manufacturing process (FDA, 1997). 
Lamotrigine (The Merck Index, 2001; Figure 1), 3,5-dia-
mino-6-(2,3-dichorophenyl)-1,2,4-triazine, [84057-84-1], 
C
9
H
7
Cl
2
N
5
, mol. wt. 256.09, is chemically unrelated with 
other antiepileptic drugs in current use. This drug is useful 
in the treatment of partial and tonic-clonic generalized 
seizures resistant to other anticonvulsant drugs (Cordioli, 
2000). It acts through stabilizing pre-synaptic membranes 
by blocking voltage-dependent sodium channels. The drug 
has also been associated with preventing aspartate and gluta-
mate release (Kliemann, 2004). The efficacy of lamotrigine 
as an add-on therapy has been well established in adults and 
children (Ben-Menachen, 2000) and was recently approved 
as monotherapy (Cheng et al., 2005).
FIGURE 1 – The chemical structure of lamotrigine.
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Although there are many studies describing the 
determination of lamotrigine in biological fluids (Coc-
ciglio et al., 1991; Sallustio, Morris, 1997; Matar et al., 
1998; Ashton et al., 1999; Botinger et al., 1999; Vidal et 
al., 1999; Angelis Stofordis et al., 1999; Barbosa, Midio, 
2000; Torra et al., 2000; Croci et al., 2001; Castel-Branco 
et al., 2001; Patil, Bodhankar, 2005; Cheng et al., 2005; 
Kuldeep, Subash, 2005), and pharmaceutical formula-
tion (Emani et al., 2006; Yousef, Taha, 2007) by several 
methods besides a dissolution test using HPLC method 
(Sripalakit et al., 2008), no dissolution test for this phar-
maceutical solid dosage form has yet been described in any 
pharmacopoeia. Therefore, this paper describes the deve-
lopment and validation of a dissolution test for lamotrigine 
in tablets using a simple, fast and inexpensive ultraviolet 
method, and performs a comparative evaluation of the 
dissolution profiles of two different formulations. The 
development and validation were carried out in complian-
ce with the United States Pharmacopeia (USP 31, 2008).
MATERIAL AND METHODS
Experimental
Instrumentation
The dissolution tests were performed on a multi-bath 
(n=7) dissolution test system Sotax AT7 (Basel, Switzer-
land), in accordance with the United States Pharmacopeia 
(USP 31, 2008) general methods.
An UV-VIS Recording Spectrophotometer UV-
160A (Shimadzu, Kyoto, Japan) at 267 nm, using 1.0 cm 
quartz cells and SPECTRA MANAGER software, was 
used for all absorbance measurements to quantify the sam-
ples of lamotrigine dissolved in the dissolution medium.
The Digimed potentiometer, model DM-20 (São 
Paulo, Brazil), was used to determine the pH of solutions.
The ultrasonic-bath UCS 5000 (Unique, São Paulo, 
Brazil) was used for deaeration of the media and prepa-
ration of solutions.
The filter used for sample filtration was a Framex® 
quantitative filter of 10 mm. A 0.45µm, 13 mm, nylon 
membrane Millex® (Millipore, São Paulo, Brazil) was 
used for mobile phase filtration in stability and solubility 
determination by the HPLC method.
A model LC-1200 series liquid chromatograph 
(Agilent, Santa Clara, CA, United States) equipped with 
G1311A Quaternary pump, ALS G1329A auto sampler, 
TCC G1316A Thermostat Column Compartment, DAD 
G1315B photodiode-array detector, SCL-10Avp system 
controller and Chemstation manager system software, 
was employed for lamotrigine stability and solubility 
determination. 
Chemicals and reagents
The lamotrigine reference substance (99.41%) was 
obtained from Cristália Produtos Químicos Farmacêuticos 
LTDA (São Paulo, Brazil). The pharmaceutical formula-
tions (Product A and Product B) containing lamotrigine 
were obtained commercially.
Product A – (reference product, Lamictal®) - labeled 
as containing 100 mg of lamotrigine and the following 
inactive ingredients (lactose, microcrystalline cellulose, 
povidone, sodium starch glycolate, ferric oxide (yellow) 
and magnesium stearate).
Product B - (Neural®) - labeled as containing 100 mg 
of lamotrigine and the following inactive ingredients 
(mannitol, pregelatinized starch, dibasic calcium phos-
phate, corn starch, sodium starch glycolate, magnesium 
stearate, and tartrazine yellow colorant).
All of the inactive ingredients were obtained from 
different local distributors. Purified water was obtained 
using a Millipore® system (São Paulo, Brazil). HPLC 
grade triethylamine and orthophosphoric acid were pur-
chased from Merck® (Darmstadt, Germany). Hydrochloric 
acid (HCl), sodium hydroxide and sodium acetate were 
purchased from Quimex® (São Paulo, Brazil). Monobasic 
potassium phosphate was obtained from Synth® (São Pau-
lo, Brazil). Glacial acetic acid was obtained from Nuclear® 
(Brazil). The 0.01 and 0.1 M HCl, 0.05 M sodium acetate 
buffer (pH 4.7), 0.05 M monobasic potassium phosphate 
buffer (pH 5.8 and 6.8) were prepared according to the 
USP (USP 31 2008).
Chromatographic conditions
A method using HPLC with UV detection at 279 nm 
was previously developed and validated in our laboratory 
for a wide range of parameters including specificity, linea-
rity, precision, accuracy and robustness. Chromatographic 
separation was achieved on an ACE® RP-18 octadecyl 
silane column (150 mm x 4.6 mm i.d., particle size 5 µm). 
The mobile phase was composed of triethylamine solution 
0.3% pH 4.0 (adjusted with 10% orthophosphoric acid) 
and methanol (62:38, v/v). The mobile phase flow rate 
was 1.0 mL.min-1 with isocratic elution and was filtered 
before use through a 0.45 µm membrane filter Millex® 
(Millipore, São Paulo, Brazil) and degassed. The injec-
tion volume was 20 µL and the column temperature was 
maintained at 25 °C. The results obtained demonstrated 
that the method is specific (there were no peaks by place-
bo solution interfering in the lamotrigine retention time), 
linear (ranging from 10.0 to 80.0 mg.mL-1 for analysis of 
variance (ANOVA) and correlation coefficient 0.9999), 
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precise (with RSD values of less than 2%), accurate by 
recovery test (98.20% to 100.46%) and robust (the changes 
in operational parameters did not cause significant diffe-
rences in the performance of chromatographic system).
Solubility determination and sink conditions
Lamotrigine sink conditions were applied and deter-
mined in different media: purified water, 0.01 M and 0.1 M 
hydrochloric acid, 0.05 M acetate buffer (pH 4.7) and 
0.05 M phosphate buffer (pH 5.8 and 6.8). Vessels (n=2) 
containing 10.0 ml of medium were pre-heated to 37°C ± 
0.5°C before adding an excess of lamotrigine (10.0 mg). 
The solutions were maintained in the bath and stirred with 
a vortex at intervals of 10 minutes. Aliquots of 10.0 mL 
were removed from each vessel after 1 and 2 hours and 
filtered through a Millipore® 0.45 µm membrane filter. Ali-
quots of 1.0 mL of the filtered solution were transferred to 
25.0 mL volumetric flasks, diluted with mobile phase and 
injected into the HPLC. Standard solution of lamotrigine 
was prepared with 40 µg.mL-1 and used to determine the 
amount of lamotrigine dissolved in different media .
Dissolution test conditions
Dissolution testing of tablets was performed with Pro-
duct A in accordance with the USP (USP 31, 2008) to define 
the dissolution test conditions. This was performed using 
paddles (USP apparatus 2) at a stirring speed of 50 rpm and 
900 mL of the different dissolution media pre-heated to 
37 °C ± 0.5 °C. Manual sampling aliquots of 10.0 ml were 
withdrawn at 5, 10, 15, 30, 45 and 60 minutes. 
After these preliminary studies, the dissolution 
test was conducted using the conditions described above 
and the medium selected was 0.01 M hydrochloric acid 
maintained at 37 ± 0.5 ºC. The profile was evaluated and a 
single point at 30 minutes was selected. After 30 minutes, 
aliquots of 10.0 mL were withdrawn from each vessel and 
filtered using a Framex® quantitative filter.
The sample solutions were prepared using the 
filtered aliquots taken from the dissolution vessels. The 
4.0 mL aliquots were transferred to 20.0 ml volumetric 
flasks with 0.01 M hydrochloric acid and analyzed on a 
UV/VIS Spectrophotometer (267 nm).
The standard solution was prepared using an amount 
of lamotrigine reference substance equivalent to 11.11 mg, 
transferred to a 20 mL volumetric flask with the dissolution 
medium. The solutions were placed in an ultrasonic-bath 
for 15 minutes. An aliquot of 2.0 mL of this standard so-
lution was transferred to a 50.0 mL volumetric flask and 
diluted with 0.01 M hydrochloric acid to give a solution 
containing 22.22 µg.mL-1. This solution was analyzed on 
a UV/VIS spectrophotometer at 267 nm.
Filtration
Filtration of the dissolution samples is usually neces-
sary to prevent undissolved drug particles from entering 
the analytical sample and removes insoluble excipients 
that otherwise cause high background or turbidity. The 
filter evaluation is necessary to verify whether it can be 
used in the dissolution test without adsorption of the drug 
into the filter (USP 31, 2008). Standard and sample solu-
tions were prepared in the dissolution medium proposed 
(0.01 M hydrochloric acid). The standard solution was 
prepared with a lamotrigine concentration of 0.11 mg.mL -1. 
This solution was placed for 15 minutes in an ultrasonic-
bath (Solution A). Four milliliters of Solution A was diluted 
in a 20.0 mL volumetric flask with 0.01 M hydrochloric 
acid – (solution without filtration). The remaining Solution 
A was filtered using a Framex® quantitative filter, and an 
aliquot of 4.0 mL was transferred to a 20.0 mL volumetric 
flask and diluted with the same solvent – (filtered solution). 
The samples were prepared with the same concentration 
of 0.11 mg.mL -1 using 0.01 M hydrochloric acid. This 
solution was maintained for 15 minutes in an ultrasonic 
bath and immediately centrifuged at 3000 rpm for 10 mi-
nutes. An aliquot of 4.0 ml was transferred to a 20.0 mL 
volumetric flask and diluted with 0.01 M hydrochloric 
acid – (solution without filtration). Another solution was 
prepared in the same manner, but instead of undergoing 
centrifugation was filtered with a Framex® quantitative 
filter, and an aliquot of 4.0 ml was transferred to a 20.0 
ml volumetric flask and diluted with the same solvent – 
(filtered solution). The standard solutions (filtered and wi-
thout filtration) and the sample solutions (centrifuged and 
filtered) were analyzed using UV determination at 267 nm.
Validation
In order to demonstrate the method’s suitability for 
use as a dissolution test, it was validated based on stability, 
specificity, linearity, precision, accuracy and robustness 
parameters (USP 31, 2008).
Stability
The standard solution stability test was performed 
in the dissolution medium selected (0.01 M hydrochloric 
acid) at 37 °C ± 0.5 °C for 2 hours and at room tempe-
rature for 24 hours. The chromatograms obtained by the 
HPLC method were evaluated and compared with a freshly 
prepared standard solution (peak area and degradation 
product formation).
Specificity
Placebo samples of both commercial products were 
prepared in their usual compositions. The placebo samples 
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were transferred to different vessels (n=3) with 900 mL of 
dissolution medium at 37 °C ± 0.5 °C and stirred for 2 h 
at 150 rpm using a paddle (USP apparatus 2). Aliquots of 
these solutions were filtered through a FRAMEX® quan-
titative filter and analyzed by the UV method (267 nm).
Linearity
A stock solut ion was prepared containing 
100 µg mL-1 of lamotrigine using 0.01 M hydrochloric 
acid as solvent. Aliquots of this solution were transferred 
to volumetric flasks to obtain final concentrations of 5, 10, 
15, 20, 25, 30 and 40 µg.mL-1. Each solution was prepared 
in triplicate. The linearity was evaluated by linear regres-
sion analysis, which was calculated by the least squares 
regression method and analysis of variance (ANOVA).
Precision
The evaluation of inter-day precision (intermediate 
precision) of the dissolution test was performed on two 
different days by different analysts. The repeatability was 
evaluated on the same day for intra-day precision in six 
vessels used for the dissolution test. The relative standard 
deviation (RSD) from the results was calculated.
Accuracy
A lamotrigine reference stock solution (2.0 mg.mL-1) 
was prepared in 0.01 M hydrochloric acid), using an 
ultrasonic-bath for 60 minutes. A recovery study was 
conducted by adding known amounts of the lamotrigine 
stock solution to the dissolution vessels containing the 
placebo solution (10, 20 and 100%) of the nominal assay 
(100 mg). Each concentration was prepared in duplicate 
and analyzed by the UV method at 267 nm.
Robustness
This was evaluated by comparing the dissolution 
medium with and without using the ultrasonic bath. Me-
dium deaeration was used to eliminate air bubbles before 
the dissolution test. The results from dissolution samples 
in nondeaerated medium and deaerated medium had to be 
compared to determine whether deaeration was necessary 
(USP 31, 2008).
RESULTS AND DISCUSSIONS
Drug solubility is an important physical-chemical 
property to be considered when selecting the dissolution 
medium and can be determined by using an excess of 
the drug in the medium followed by stirring, filtration 
and quantification of the dissolved drug (USP 31, 2008). 
This is the property that most affects the drug dissolution 
velocity ( Abdou, 1989). Lamotrigine presents limited 
solubility in water (0.17 mg.mL-1) at 25 °C, and its solu-
bility decreases in proportion to pH increase in, since this 
drug is a weak basis and is not ionized at a pH greater than 
its pKa (5.7). Dissolution characteristics must be tested 
in the physiological pH range (1.2 to 6.8) for immediate 
drug release, and can be considered fast drug dissolution 
when no less than 85% of the drug amount is dissolved 
within 15 minutes (USP 31, 2008; Yu et al., 2002). Sink 
condition is defined to be no less than three times the 
necessary volume to obtain a saturated drug solution 
(Marques, Brown, 2002). This sink condition was reached 
for the media in which lamotrigine solubility was higher 
than 333.33 μg.mL-1, i.e. three times the nominal dose in 
900 mL. This occurred in the following media: 0.01 M 
hydrochloric acid, 0.1 M hydrochloric acid, acetate bu-
ffer pH 4.7, phosphate buffer pH 5.8 and after 2 hours in 
phosphate buffer pH 6.8. Sink conditions were not reached 
in purified water or in phosphate buffer pH 6.8, 1 hour 
(Table I). In HCl media (0.1 M and 0.01 M) however, the 
solubility must have been higher since all the drug dissol-
ved. Water is not an ideal dissolution medium for several 
reasons. First, because the variability of the quality of the 
water from different sources, and second, the variability 
of the pH from day to day and also during the run, where 
this depends on the active substance and excipients (FDA, 
1997; USP 31, 2008).
The dissolution profile at six points (5, 10, 15, 30, 
45 and 60 minutes) of Product A in the evaluated media 
showed that lamotrigine dissolved more than 85% in 15 
minutes (Figure 2). Thus, for a very rapidly dissolving 
drug, a simple one point dissolution test is all that may 
be needed and for immediate-release dosage forms, the 
duration of the procedure is typically 30 to 60 minutes 
(Amidon et al., 1995; USP 31, 2008). This was expected 
from the results obtained in the solubility test. The choice 
TABLE I - Solubility of lamotrigine in different media at 
37 °C ± 0.5 °C.
Medium Solubility 
(1 hour) 
(µg.mL-1)
Solubility 
(2 hours) 
(µg.mL-1)
Purified water 248.5 289.6
0.01 M Hydrochloric acid 1117.8 1091.8
0.1 M Hydrochloric acid 1048.0 1140.2
Acetate buffer pH 4.7 802.7 834.0
 Phosphate buffer pH 5.8 337.1 401.7
Phosphate buffer pH 6.8 311.8 381.7
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of the medium was 0.01 M hydrochloric acid due to its 
good solubility, accessibility, low cost and the fact that it 
is a typical dissolution medium (Marques, Brown, 2002). 
The initial parameters for filtration and solution 
stability must be established prior to the completion of any 
dissolution samples (Fortunato, 2005). The results between 
the solutions (filtered or centrifuged) must be very similar 
for acceptance of the filter (Skoug, Freeman, 1996). The 
evaluation of the filter demonstrated that the FRAMEX® 
can be used safely during the dissolution test, since there 
was no significant drug adsorption. The difference in values 
between the solutions was less than 2%. In order to evaluate 
lamotrigine stability in 0.01 M hydrochloric acid, chroma-
tograms were obtained. The results (Figure 3) showed that 
the solutions remained stable and that no degradation peaks 
formed. According to the literature (USP 31, 2008), the 
acceptable range for solution stability is within 98-102% of 
the initial value. The values obtained were less than 1% in 
both conditions evaluated (99.90% for solution maintained 
at 37 °C ± 0.5 °C for 2h, and 99.25% at room temperature for 
24 h) compared with a freshly prepared standard solution. 
Therefore, it was possible to guarantee the integrity of the 
drug during all the analysis time.
The specificity analysis of placebo solutions revea-
led that the UV method (267 nm) suffered no interference 
from the formulation for either of the products evaluated 
(A and B), demonstrating this method to be specific (Fi-
gure 4). Since there were not inactive ingredients interfe-
ring with the wavelength selected (267 nm), UV was the 
method selected for lamotrigine quantification (Fortunato, 
2005). Generally, the simplest assay method to develop 
utilizes UV/VIS spectrophotometry. This method is fre-
quently used in quality control of pharmaceutical products 
due to the potential of the great majority of the drugs that 
absorb energy at these wavelengths. Lamotrigine presents 
a structure with aromatic rings, allowing absorption in 
the UV region. The UV method requires no expensive or 
complex equipment, and needs no toxic solvents. (Bakshi, 
2002). The preferred method of analysis is spectropho-
tometric determination because results can be obtained 
faster, the analysis is simpler and fewer solvents are used, 
making this valuable in routine analysis (USP 31, 2008; 
Skoug, Freeman, 1996). 
To assess linearity, three calibration curves for lamo-
trigine were constructed, plotting concentration (µg mL-1) 
versus absorbance. This demonstrated linearity, showing 
a correlation coefficient of approximately 0.9999 in the 
concentration range studied (4.0-40.0 µg.mL-1). The re-
presentative linear equation was y= 0.02723x + 0.00229. 
The data were validated by means of the analysis of va-
riance (ANOVA), which demonstrated significant linear 
regression and no significant linearity deviation (p<0.05) 
(Farmacopéia Brasileira, 1988).
The precision results of the dissolution method were 
evaluated by analyzing repeatability and intermediate 
precision. The assay evidenced a low RSD ranging from 
0.70 to 1.52 for intra-day precision and 1.23 for inter-day 
precision. RSD values lower than 2% indicated the good 
precision of this method.
Degree of accuracy expresses the concordance be-
tween the accepted value and the value found. The measu-
red recovery is typically 95-105% (USP 31, 2008). Mean 
recovery obtained was in the range of 98.46 to 103.59%, 
which indicated good accuracy of the method.
In the evaluation of method robustness, the presen-
ce of possible air bubbles in the dissolution medium did 
not interfere in the dissolution profile of lamotrigine in 
tablets. Based on the results obtained, and considering 
the percentage of dissolved drug (102.85% in deaerated 
medium and 101.57% in nondeaerated medium), the use of 
an ultra-sonic bath is not necessary because the difference 
between the results was not significant (1.28%).
Lamotrigine BCS (Biopharmaceutics Classification 
System) is class I, with high solubility and high permeabi-
FIGURE 2 - Dissolution profile of Product A in different media 
at 5, 10, 15, 30, 45 and 60 minutes.
FIGURE 3 - Chromatograms of lamotrigine reference standard. 
(A) 2 hours at 37 °C ± 0.5 °C, (B) 24 hours at room temperature 
and (C) freshly prepared standard
M. T. Martins, C. S. Paim, M. Steppe184
lity, and these products need not be subjected to a profile 
comparison if they can be shown to release 85% or more 
of the active drug substance within 15 minutes (Ander-
son, 2008). Consequently, it is not necessary to calculate 
f1 (measure of the percentage error between two curves 
over all time points) and f2 (logarithmic transformation of 
the sum squared error of differences between the test and 
reference over all time points), since they have lost their 
discriminative power (Brasil, 2004). Acceptance criteria 
for the amount of active ingredient dissolved, expressed as 
a percentage of the labeled content (Q), are in the range of 
75% to 80% dissolved ingredient (USP 31, 2008). In this 
study on lamotrigine, we can propose an acceptance crite-
ria of 80% ingredient dissolved in 30 minutes. The results 
obtained for the mean amount of lamotrigine dissolved for 
both products in 30 minutes were (Product A – 101.41% and 
Product B – 98.37%) and the comparison of their profiles 
is shown in Figure 5. Amindon et al. (1995) suggested that 
products with high solubility such as lamotrigine can be 
considered bioequivalent if they allow 85% of drug release 
within 15 minutes. The products studied (A and B) were in 
agreement with this specification, but in vivo studies need 
to be carried out to guarantee the bioequivalence of the 
products. The amount of dissolved drug can be influenced 
by many factors including the manufacturing process, for-
mulation, humidity and substances properties (Skoug et al., 
1996). The comparison of the dissolution profiles allowed 
differences between the formulations to be observed.
CONCLUSIONS
The dissolution test developed and validated for 
lamotrigine was considered satisfactory. The method has 
the advantages of being very easy, fast and simple. The 
method was carefully assessed to guarantee the stability 
of the drug during the analysis time. The method is suita-
ble for its purpose and could be applied in routine quality 
control of lamotrigine in tablet formulation since there is 
no official monograph for this drug in the pharmacopoeias.
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